Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosis

Journal of Molecular Signaling

Volumn 7, Issue , 2012, Pages

  War, Sajad A ^a   Kumar, Ujendra ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apoptosis; G protein coupled receptor (GPCR); Heterodimerization; Photobleaching fluorescence resonance energy transfer (Pb FRET); Somatostatin; Somatostatin receptors

Indexed keywords

EID: 84861637165     PISSN: None     EISSN: 17502187     Source Type: Journal    
DOI: 10.1186/1750-2187-7-5     Document Type: Article

References (55)

1. Terrillon S, Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep 2004, 5:30-34. 10.1038/sj.embor.7400052, 1298963, 14710183.
2. Prinster SC, Hague C, Hall RA. Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol Rev 2005, 57:289-298. 10.1124/pr.57.3.1, 16109836.
3. Grant M, Alturaihi H, Jaquet P, Collier B, Kumar U. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol 2008, 22:2278-2292. 10.1210/me.2007-0334, 18653781.
4. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999, 20:157-198. 10.1006/frne.1999.0183, 10433861.
5. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001, 28:836-846. 10.1007/s002590100541, 11504080.
6. Grant M, Collier B, Kumar U. Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J Biol Chem 2004, 279:36179-36183. 10.1074/jbc.M407310200, 15231824.
7. Grant M, Kumar U. The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul Pept 2010, 159:3-8. 10.1016/j.regpep.2009.08.011, 19748526.
8. Somvanshi RK, Billova S, Kharmate G, Rajput PS, Kumar U. C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. Cell Signal 2009, 21:1396-1414. 10.1016/j.cellsig.2009.04.007, 19426801.
9. War SA, Somvanshi RK, Kumar U. Somatostatin receptor-3 mediated intracellular signaling and apoptosis is regulated by its cytoplasmic terminal. Biochim Biophys Acta 2011, 1813:390-402. 10.1016/j.bbamcr.2010.12.015, 21194548.
10. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000, 288:154-157. 10.1126/science.288.5463.154, 10753124.
11. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 2007, 19:2304-2316. 10.1016/j.cellsig.2007.07.007, 17706924.
12. Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, Kreienkamp HJ, Hollt V, Schulz S. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 2001, 276:14027-14036.
13. Roth A, Kreienkamp HJ, Meyerhof W, Richter D. Phosphorylation of four amino acid residues in the carboxyl terminus of the rat somatostatin receptor subtype 3 is crucial for its desensitization and internalization. J Biol Chem 1997, 272:23769-23774. 10.1074/jbc.272.38.23769, 9295322.
14. Roosterman D, Brune NE, Kreuzer OJ, Feld M, Pauser S, Zarse K, Steinhoff M, Meyerhof W. Intracellular degradation of somatostatin-14 following somatostatin-receptor3-mediated endocytosis in rat insulinoma cells. FEBS J 2008, 275:4728-4739. 10.1111/j.1742-4658.2008.06606.x, 18702662.
15. Nishimoto S, Nishida E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep 2006, 7:782-786. 10.1038/sj.embor.7400755, 1525153, 16880823.
16. Nishida E, Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 1993, 18:128-131. 10.1016/0968-0004(93)90019-J, 8388132.
17. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terreni MR, Khalaf S, Jordan S, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 2006, 155:371-379. 10.1530/eje.1.02213, 16868153.
18. Berra E, Diaz-Meco MT, Moscat J. The activation of p38 and apoptosis by the inhibition of Erk is antagonized by the phosphoinositide 3-kinase/Akt pathway. J Biol Chem 1998, 273:10792-10797. 10.1074/jbc.273.17.10792, 9553146.
19. Kharmate G, Rajput PS, Watt HL, Somvanshi RK, Chaudhari N, Qiu X, Kumar U. Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling. Biochim Biophys Acta 2011, 1813:1172-1189. 10.1016/j.bbamcr.2011.03.006, 21419811.
20. Kharmate G, Rajput PS, Watt HL, Somvanshi RK, Chaudhari N, Qiu X, Kumar U. Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in the presence of somatostatin receptor 5 modulate signaling pathways. Endocrinology 2011, 152:931-945. 10.1210/en.2010-0940, 21190959.
21. Watt HL, Kharmate GD, Kumar U. Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell Signal 2009, 21:428-439. 10.1016/j.cellsig.2008.11.012, 19070659.
22. Lahlou H, Saint-Laurent N, Esteve JP, Eychene A, Pradayrol L, Pyronnet S, Susini C. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 2003, 278:39356-39371. 10.1074/jbc.M304524200, 12878607.
23. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003, 2:999-1017. 10.1038/nrd1255, 14654798.
24. Smalley KS, Feniuk W, Sellers LA, Humphrey PP. The pivotal role of phosphoinositide-3 kinase in the human somatostatin sst(4) receptor-mediated stimulation of p44/p42 mitogen-activated protein kinase and extracellular acidification. Biochem Biophys Res Commun 1999, 263:239-243. 10.1006/bbrc.1999.1351, 10486283.
25. Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C, Susini C. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci 2004, 1014:121-131. 10.1196/annals.1294.012, 15153426.
26. Sellers LA. Prolonged activation of extracellular signal-regulated kinase by a protein kinase C-dependent and N17Ras-insensitive mechanism mediates the proliferative response of G(i/o)-coupled somatostatin sst(4) receptors. J Biol Chem 1999, 274:24280-24288. 10.1074/jbc.274.34.24280, 10446204.
27. Alderton F, Humphrey PP, Sellers LA. High-intensity p38 kinase activity is critical for p21(cip1) induction and the antiproliferative function of G(i) protein-coupled receptors. Mol Pharmacol 2001, 59:1119-1128.
28. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009, 9:537-549. 10.1038/nrc2694, 19629069.
29. Chuang SM, Wang IC, Yang JL. Roles of JNK, p38 and ERK mitogen-activated protein kinases in the growth inhibition and apoptosis induced by cadmium. Carcinogenesis 2000, 21:1423-1432. 10.1093/carcin/21.7.1423, 10874022.
30. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996, 10:1688-1696. 10.1210/me.10.12.1688, 8961277.
31. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008, 13:822-840. 10.2741/2723, 17981591.
32. Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M, Gelmini P, Luciani P, Peri A, Mantovani G, Bosari S, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 2006, 13:955-962. 10.1677/erc.1.01191, 16954443.
33. Zou Y, Xiao X, Li Y, Zhou T. Somatostatin analogues inhibit cancer cell proliferation in an SSTR2-dependent manner via both cytostatic and cytotoxic pathways. Oncol Rep 2009, 21:379-386.
34. Zhou T, Xiao X, Xu B, Li H, Zou Y. Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathways. Acta Oncologica 2009, 48:401-410. 10.1080/02841860802314746, 18759148.
35. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, Albini A. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003, 144:1574-1584. 10.1210/en.2002-220949, 12639942.
36. Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996, 137:4046-4049. 10.1210/en.137.9.4046, 8756582.
37. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 2002, 277:19762-19772. 10.1074/jbc.M110373200, 11896051.
38. Roosterman D, Kreuzer OJ, Brune N, Cottrell GS, Bunnett NW, Meyerhof W, Steinhoff M. Agonist-induced endocytosis of rat somatostatin receptor 1. Endocrinology 2007, 148:1050-1058.
39. Rohrer SP, Schaeffer JM. Identification and characterization of subtype selective somatostatin receptor agonists. J Physiol Paris 2000, 94:211-215. 10.1016/S0928-4257(00)00215-1, 11087999.
40. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC, Patel YC. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 1999, 48:77-85. 10.2337/diabetes.48.1.77, 9892225.
41. Grant M, Patel RC, Kumar U. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem 2004, 279:38636-38643. 10.1074/jbc.M406276200, 15247250.
42. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000, 275:7862-7869. 10.1074/jbc.275.11.7862, 10713101.
43. Somvanshi RK, War SA, Chaudhari N, Qiu X, Kumar U. Receptor specific crosstalk and modulation of signaling upon heterodimerization between beta1-adrenergic receptor and somatostatin receptor-5. Cell Signal 2011, 23:794-811. 10.1016/j.cellsig.2011.01.002, 21238583.
44. Somvanshi RK, Chaudhari N, Qiu X, Kumar U. Heterodimerization of beta2 adrenergic receptor and somatostatin receptor 5: Implications in modulation of signaling pathway. J Mol Signal 2011, 6:9. 10.1186/1750-2187-6-9, 3166894, 21838893.
45. Pages P, Benali N, Saint-Laurent N, Esteve JP, Schally AV, Tkaczuk J, Vaysse N, Susini C, Buscail L. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J Biol Chem 1999, 274:15186-15193. 10.1074/jbc.274.21.15186, 10329727.
46. Cattaneo MG, Taylor JE, Culler MD, Nisoli E, Vicentini LM. Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett 2000, 481:271-276. 10.1016/S0014-5793(00)02012-3, 11007977.
47. Dent P, Wang Y, Gu YZ, Wood SL, Reardon DB, Mangues R, Pellicer A, Schonbrunn A, Sturgill TW. S49 cells endogenously express subtype 2 somatostatin receptors which couple to increase protein tyrosine phosphatase activity in membranes and down-regulate Raf-1 activity in situ. Cell Signal 1997, 9:539-549. 10.1016/S0898-6568(97)00048-X, 9419818.
48. Thellung S, Villa V, Corsaro A, Pellistri F, Venezia V, Russo C, Aceto A, Robello M, Florio T. ERK1/2 and p38 MAP kinases control prion protein fragment 90-231-induced astrocyte proliferation and microglia activation. Glia 2007, 55:1469-1485. 10.1002/glia.20559, 17705195.
49. Florio T, Yao H, Carey KD, Dillon TJ, Stork PJ. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol Endocrinol 1999, 13:24-37. 10.1210/me.13.1.24, 9892010.
50. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 2002, 4:556-564.
51. Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, Clayton RN, Jenkins PJ, Monson JP, Besser GM, et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 1999, 84:3823-3830. 10.1210/jc.84.10.3823, 10523037.
52. Bamberger AM, Riethdorf L, Milde-Langosch K, Bamberger CM, Thuneke I, Erdmann I, Schulte HM, Loning T. Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia. Virchows Arch 1999, 434:423-428. 10.1007/s004280050361, 10389625.
53. Bamberger CM, Fehn M, Bamberger AM, Ludecke DK, Beil FU, Saeger W, Schulte HM. Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur J Endocrinol 1999, 140:250-255. 10.1530/eje.0.1400250, 10216521.
54. Wu DW, Liu WS, Wang J, Chen CY, Cheng YW, Lee H. Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer. Clin Cancer Res 2011, 17:1895-1905. 10.1158/1078-0432.CCR-10-2316, 21325288.
55. Romics I, Banfi G, Szekely E, Krenacs T, Szende B. Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer. Pathol Oncol Res 2008, 14:307-311. 10.1007/s12253-008-9042-z, 18415709.